ORI Capital, the China- and U.S.-based venture investor behind the biotechnology sector’s largest initial public offering this year, has raised a new life sciences fund, the firm said Thursday.

ORI Capital周四表示，该公司已募集到一只新的生命科学基金。ORI Capital是生物技术行业今年最大规模首次公开募股背后的中美风险投资者。

The $260 million fund is the second for ORI since the firm was launched in 2015 by Simone Song, formerly the head of health banking for China at Goldman Sachs. ORI closed its first fund one year later, focusing on investments in cancer, heart and neurodegenerative diseases.

这项2.6亿美元的基金是ORI自2015年由前高盛（Goldman Sachs）中国健康银行主管Simone Song创立以来的第二笔基金。一年后，ORI关闭了第一只基金，专注于癌症、心脏和神经退行性疾病的投资。

The firm’s approach is built around a database it calls “Orizon.” ORI uses the database to sift through thousands of young companies and experimental medicines, weighing their prospects against either marketed drugs or others in development. It prioritizes investments in companies “tackling significant diseases with high mortality rates,” Song said in a statement..

该公司的方法是围绕一个称为“Orizon”的数据库建立的。ORI使用该数据库筛选数千家年轻公司和实验药物，将其前景与市售药物或其他正在开发的药物进行权衡。宋在一份声明中说，它优先投资于“应对高死亡率重大疾病”的公司。。

The approach has already resulted in some notable payouts. ORI invested in Semma Therapeutics, the diabetes cell therapy developer Vertex Pharmaceuticals bought for $950 million in 2019. It also backed immune disease drug developer Kymab before its $1.1 billion acquisition by Sanofi. Drugs from both startups are now in clinical testing.

这种方法已经产生了一些值得注意的支出。ORI投资于Semma Therapeutics，糖尿病细胞治疗开发商Vertex Pharmaceuticals于2019年以9.5亿美元收购。在赛诺菲斥资11亿美元收购免疫疾病药物开发公司Kymab之前，该公司还为其提供了支持。两家初创公司的药物目前都在进行临床试验。

Song told Bloomberg last year the firm believed it would exit most of the investments from its first fund by the end of 2024 with an expected 3.6-times return on invested capital..

宋去年告诉彭博社，该公司相信，到2024年底，它将退出第一只基金的大部分投资，预计投资回报率将达到3.6倍。。

More recently, ORI saw another one of its investments, cancer drug startup CG Oncology, raise $380 million in an IPO in January. That offering was the biotech sector’s largest this year and the most lucrative IPO since last May. according to BioPharma Dive data. ORI was CG’s top shareholder, owning an 11% stake in the company prior to the offering..

最近，ORI看到其另一项投资，抗癌药物初创公司CG Oncology，在1月份的首次公开募股中筹集了3.8亿美元。根据BioPharma Dive的数据，这是生物技术行业今年最大规模的首次公开募股，也是自去年5月以来利润最丰厚的首次公开募股。ORI是CG的最大股东，在发行前拥有该公司11%的股份。。

The firm typically targets early- to mid-stage companies. Going forward, it is eyeing newer drugmaking approaches such as chemical drugs that target RNA, so-called protein degraders, cell therapies and RNA-based medicines.

该公司的目标通常是早期到中期的公司。展望未来，它正在寻找新的制药方法，例如靶向RNA的化学药物，所谓的蛋白质降解剂，细胞疗法和基于RNA的药物。

“We are in a golden-era of innovation across the intersection of AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease,” Song said in the statement, adding that the current environment “provides an attractive opportunity for investing in the next generation of leading biotech companies.”.

宋在声明中说：“我们正处于人工智能和生物学交叉点创新的黄金时代，技术突破正在创造诊断和治疗疾病的新方法。”他补充说，目前的环境“为投资下一代领先的生物技术公司提供了一个有吸引力的机会。”。

ORI isn’t alone in raising a new fund. Since the second half of last year, OrbiMed, Westlake Village Biopartners, Abingworth and Bioluminescence Ventures have all closed new funds. Arch Venture Partners and Flagship Pioneering are each working on $3 billion funds as well.

ORI并不是唯一一个筹集新基金的人。自去年下半年以来，OrbiMed、Westlake Village Biopartners、Abingworth和Biolescence Ventures都关闭了新基金。Arch Venture Partners和Flagship Exponential各自也在投入30亿美元的资金。